<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T09:53:32Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10425486" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10425486</identifier>
        <datestamp>2023-08-16</datestamp>
        <setSpec>springeropen</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article" dtd-version="1.3">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Intensive Care Med</journal-id>
              <journal-id journal-id-type="iso-abbrev">Intensive Care Med</journal-id>
              <journal-title-group>
                <journal-title>Intensive Care Medicine</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0342-4642</issn>
              <issn pub-type="epub">1432-1238</issn>
              <publisher>
                <publisher-name>Springer Berlin Heidelberg</publisher-name>
                <publisher-loc>Berlin/Heidelberg</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10425486</article-id>
              <article-id pub-id-type="pmcid">PMC10425486</article-id>
              <article-id pub-id-type="pmc-uid">10425486</article-id>
              <article-id pub-id-type="pmid">37470832</article-id>
              <article-id pub-id-type="pmid">37470832</article-id>
              <article-id pub-id-type="publisher-id">7135</article-id>
              <article-id pub-id-type="doi">10.1007/s00134-023-07135-3</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Original</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Safety and efficacy of artesunate treatment in severely injured patients with traumatic hemorrhage. The TOP-ART randomized clinical trial</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8180-8842</contrib-id>
                  <name>
                    <surname>Shepherd</surname>
                    <given-names>Joanna M.</given-names>
                  </name>
                  <address>
                    <email>j.m.shepherd@qmul.ac.uk</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ross</surname>
                    <given-names>Jennifer</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Anton</surname>
                    <given-names>Lourdes</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rourke</surname>
                    <given-names>Claire</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Brentnall</surname>
                    <given-names>Adam R.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Tarning</surname>
                    <given-names>Joel</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff5">5</xref>
                  <xref ref-type="aff" rid="Aff6">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>White</surname>
                    <given-names>Nicholas J.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff5">5</xref>
                  <xref ref-type="aff" rid="Aff6">6</xref>
                </contrib>
                <contrib contrib-type="author" equal-contrib="yes">
                  <name>
                    <surname>Thiemermann</surname>
                    <given-names>Christoph</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff7">7</xref>
                </contrib>
                <contrib contrib-type="author" equal-contrib="yes">
                  <name>
                    <surname>Brohi</surname>
                    <given-names>Karim</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.4868.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 2171 1133</institution-id><institution>Centre for Trauma Sciences, </institution><institution>The Blizard Institute, Queen Mary University of London, </institution></institution-wrap>London, E1 4AT UK </aff>
                <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.5072.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 0304 893X</institution-id><institution>Chelsea Research Center, The Royal Marsden NHS Foundation Trust, </institution></institution-wrap>2nd Floor Wallace Wing, 203 Fulham Rd, Chelsea, London, SW3 6JJ UK </aff>
                <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.436365.1</institution-id><institution-id institution-id-type="ISNI">0000 0000 8685 6563</institution-id><institution>NHS Blood and Transplant Clinical Trials Unit, Cambridge Blood Centre, </institution></institution-wrap>Long Road, Cambridge, CB20PT UK </aff>
                <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.4868.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 2171 1133</institution-id><institution>Centre for Evaluation and Methods, </institution><institution>Wolfson Institute of Population Health, Queen Mary University of London, </institution></institution-wrap>Charterhouse Square, London, EC1M 6BQ UK </aff>
                <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.10223.32</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0490</institution-id><institution>Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, </institution><institution>Mahidol University, </institution></institution-wrap>Bangkok, Thailand </aff>
                <aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.4991.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8948</institution-id><institution>Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, </institution><institution>University of Oxford, </institution></institution-wrap>Oxford, UK </aff>
                <aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.4868.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 2171 1133</institution-id><institution>Centre for Translational Medicine and Therapeutics, </institution><institution>The William Harvey Research Institute, Queen Mary University of London, </institution></institution-wrap>Charterhouse Square, London, EC1M 6BQ UK </aff>
              </contrib-group>
              <pub-date pub-type="epub">
                <day>20</day>
                <month>7</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>20</day>
                <month>7</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <year>2023</year>
              </pub-date>
              <volume>49</volume>
              <issue>8</issue>
              <fpage>922</fpage>
              <lpage>933</lpage>
              <history>
                <date date-type="received">
                  <day>16</day>
                  <month>2</month>
                  <year>2023</year>
                </date>
                <date date-type="accepted">
                  <day>27</day>
                  <month>5</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s) 2023</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
                  <license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p>
                </license>
              </permissions>
              <abstract id="Abs1">
                <sec>
                  <title>Purpose</title>
                  <p id="Par1">This study aimed at determining whether intravenous artesunate is safe and effective in reducing multiple organ dysfunction syndrome in trauma patients with major hemorrhage.</p>
                </sec>
                <sec>
                  <title>Methods</title>
                  <p id="Par2">TOP-ART, a randomized, blinded, placebo-controlled, phase IIa trial, was conducted at a London major trauma center in adult trauma patients who activated the major hemorrhage protocol. Participants received artesunate or placebo (2:1 randomization ratio) as an intravenous bolus dose (2.4 mg/kg or 4.8 mg/kg) within 4 h of injury. The safety outcome was the 28-day serious adverse event (SAE) rate. The primary efficacy outcome was the 48 h sequential organ failure assessment (SOFA) score. The per-protocol recruitment target was 105 patients.</p>
                </sec>
                <sec>
                  <title>Results</title>
                  <p id="Par3">The trial was terminated after enrolment of 90 patients because of safety concerns. Eighty-three participants received artesunate (<italic>n</italic> = 54) or placebo (<italic>n</italic> = 29) and formed the safety population and 75 met per-protocol criteria (48 artesunate, 27 placebo). Admission characteristics were similar between groups (overall 88% male, median age 29 years, median injury severity score 22), except participants who received artesunate were more shocked (median base deficit 9 vs. 4.7, <italic>p</italic> = 0.042). SAEs occurred in 17 artesunate participants (31%) vs. 5 who received placebo (17%). Venous thromboembolic events (VTE) occurred in 9 artesunate participants (17%) vs. 1 who received placebo (3%). Superiority of artesunate was not supported by the 48 h SOFA score (median 5.5 artesunate vs. 4 placebo, <italic>p</italic> = 0.303) or any of the trial’s secondary endpoints.</p>
                </sec>
                <sec>
                  <title>Conclusion</title>
                  <p id="Par4">Among critically ill trauma patients, artesunate is unlikely to improve organ dysfunction and might be associated with a higher VTE rate.</p>
                </sec>
                <sec>
                  <title>Supplementary Information</title>
                  <p>The online version contains supplementary material available at 10.1007/s00134-023-07135-3.</p>
                </sec>
              </abstract>
              <kwd-group xml:lang="en">
                <title>Keywords</title>
                <kwd>Multiple organ dysfunction syndrome</kwd>
                <kwd>Major trauma</kwd>
                <kwd>Hemorrhage</kwd>
                <kwd>Artesunate</kwd>
              </kwd-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010269</institution-id>
                      <institution>Wellcome Trust</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>101012/Z/13/Z</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Thiemermann</surname>
                      <given-names>Christoph</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
              </funding-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution>Department of Health (UK)</institution>
                  </funding-source>
                  <award-id>HICFR7405</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Thiemermann</surname>
                      <given-names>Christoph</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>issue-copyright-statement</meta-name>
                  <meta-value>© Springer-Verlag GmbH Germany, part of Springer Nature and European Society of Intensive Care Medicine 2023</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec id="d32e425">
              <title>Take-Home Message</title>
              <p id="Par6">
                <table-wrap id="Taba">
                  <table frame="hsides" rules="groups">
                    <tbody>
                      <tr>
                        <td align="left" colspan="2">This single-center randomized control trial showed that intravenous artesunate did not reduce multiple organ dysfunction in critically injured patients with trauma hemorrhage. In this patient cohort, artesunate may be associated with increased rates of venous thromboembolism.</td>
                      </tr>
                    </tbody>
                  </table>
                </table-wrap>
              </p>
            </sec>
            <sec id="Sec2">
              <title>Introduction</title>
              <p id="Par7">Multiple organ dysfunction syndrome (MODS) is common after major trauma, affecting up to two thirds of patients with critical injuries [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Post-trauma MODS is associated with a mortality over 20% and poor long-term outcomes in those who survive [<xref ref-type="bibr" rid="CR1">1</xref>–<xref ref-type="bibr" rid="CR3">3</xref>]. Prolonged critical care and hospital admissions place substantial economic burdens on healthcare systems [<xref ref-type="bibr" rid="CR4">4</xref>]. Current management is supportive and there are no specific pharmacological agents that prevent organ dysfunction [<xref ref-type="bibr" rid="CR5">5</xref>]. A therapeutic agent that reduces the incidence, severity or duration of MODS could have a major global impact on patient outcomes and healthcare resource utilization.</p>
              <p id="Par8">Artesunate, a semi-synthetic artemisinin derived from the plant <italic>Artemisia annua</italic>, is used globally as the first line treatment for severe malaria [<xref ref-type="bibr" rid="CR6">6</xref>]. The pharmacological effects of artemisinins extend beyond eradication of Plasmodium to include cytotoxicity against cancer cells, viruses and fungi [<xref ref-type="bibr" rid="CR7">7</xref>–<xref ref-type="bibr" rid="CR10">10</xref>] and they demonstrate powerful anti-inflammatory effects in experimental asthma, pancreatitis, arthritis and sepsis [<xref ref-type="bibr" rid="CR11">11</xref>–<xref ref-type="bibr" rid="CR14">14</xref>]. We recently discovered that intravenous artesunate (2.4 or 4.8 mg/kg at 90min after hemorrhage) reduces organ dysfunction caused by severe hemorrhage and resuscitation in the rat. Subsequent investigation into the potential mechanism of action (MOA) of artesunate (using RNA-seq transcriptomics and pathway analysis) revealed pro-survival and anti-inflammatory properties. Artesunate activates the Akt-endothelial nitric oxide synthase (eNOS) cell survival pathway and inhibits a range of pro-inflammatory molecules, including interleukin-1 receptor-associated kinase 1 (IRAK1), forkhead box O4 (FOXO4), glycogen synthase kinase-3β (GSK-3β) and transcription factor nuclear factor kappa B (NF-κB) [<xref ref-type="bibr" rid="CR15">15</xref>]. Artesunate also demonstrates cardioprotective effects in rat models of myocardial ischaemia and reperfusion, which are associated with activation of RISK (PI3K/Akt/ERK ½) and STAT3 (SAFE) pathways, activation of eNOS and inhibition of GSK-3β and NF-κB [<xref ref-type="bibr" rid="CR16">16</xref>]. Similar molecular pathways are implicated in humans during the hyperacute period after critical injury [<xref ref-type="bibr" rid="CR17">17</xref>].</p>
              <p id="Par9">Artesunate is safe, simple to administer, and the dose does not require adjustment in patients with renal or liver dysfunction [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. The recommended intravenous bolus dose in malaria is 2.4 mg/kg although safety studies in humans show tolerance in doses up to 18 mg/kg [<xref ref-type="bibr" rid="CR19">19</xref>–<xref ref-type="bibr" rid="CR21">21</xref>]. Artesunate has been used in millions of malaria patients without major adverse effects [<xref ref-type="bibr" rid="CR22">22</xref>–<xref ref-type="bibr" rid="CR27">27</xref>]. The potential benefit of artesunate in reducing MODS after trauma haemorrhage, coupled with an extensive pre-existing favourable safety profile in humans, provided a strong rationale for proceeding to early phase II studies examining the use of artesunate in patients with major trauma hemorrhage.</p>
              <p id="Par10">The primary objectives of this study were to evaluate the safety and efficacy of early artesunate administration in a cohort of severely injured and bleeding trauma patients. We designed and conducted a phase IIa single-center randomized control trial of artesunate in major trauma patients at risk of developing MODS at a single major trauma center in the United Kingdom (UK).</p>
            </sec>
            <sec id="Sec3">
              <title>Methods</title>
              <sec id="Sec4">
                <title>Design and setting</title>
                <p id="Par11">A prospective single-center randomized placebo-controlled phase IIa trial of an investigational medicinal product (IMP), intravenous artesunate, was conducted at the Royal London Hospital Major Trauma Centre (London, UK). Ethical approvals were granted by London City and East Research Ethics Committee (reference: 16/LO/003) and the report follows Consolidated Standards of Reporting Trials guidance [<xref ref-type="bibr" rid="CR28">28</xref>]. Full methodological details are available in the trial protocol (Supplementary material 1) and statistical analysis plan (Supplementary material 2).</p>
              </sec>
              <sec id="Sec5">
                <title>Participants</title>
                <p id="Par12">Adult trauma patients (16 years old and over) were eligible for inclusion if they activated the local massive hemorrhage protocol (MHP). The criteria for MHP activation were a systolic blood pressure &lt; 90 mmHg, AND suspected haemorrhage, AND minimal response to small volume fluid resuscitation. This participant group was selected based on previous studies that identified high base rates of MODS (approximately 30%) in this population [<xref ref-type="bibr" rid="CR29">29</xref>]. Participant agreement or agreement on behalf of incapacitated patients was required before enrolment. Exclusion criteria were as follows: admission &gt; 2 h after injury; intervention not attainable within 4 h of injury; patient not expected to survive to reach the 48 h primary efficacy endpoint; severe traumatic brain injury (TBI); pregnancy or breastfeeding; suspected non-hemorrhagic shock; MHP activation &gt; 1 h after arrival; concurrent participation in another clinical trial of an IMP, and known allergy to artesunate.</p>
              </sec>
              <sec id="Sec6">
                <title>Informed consent procedures</title>
                <p id="Par13">Due to the emergency nature of the trial intervention, most participants were incapacitated at the time of eligibility (e.g., critical injury, mechanical ventilation, sedation). Consent on behalf of incapacitated participants was obtained from relatives (if present and appropriate), or two doctors (one independent of the trial), consistent with national and international guidance [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. Once a participant regained capacity, their informed consent was sought for continuation in the trial. For participants that did not regain capacity, consent for continuation was sought from a relative or other appropriate representative.</p>
              </sec>
              <sec id="Sec7">
                <title>Study intervention</title>
                <p id="Par14">Intravenous artesunate in this trial was administered under a clinical trial authorization. A good manufacturing practice formulation of artesunate was provided free of charge by Sigma Tau (now Alfa-Wassermann Spa, Italy). Approval was granted by the Medicines and Healthcare products Regulation Authority (ref: 21313/0052/001-0001). Artesunate was supplied as crystalline powder that required re-constitution with diluent (10 mg/ml, phosphate buffer solution) immediately before delivery. The placebo consisted of diluent drawn to the equivalent volume necessary to reconstitute artesunate. Artesunate or placebo was administered as a single intravenous bolus dose within 4 h of injury.</p>
              </sec>
              <sec id="Sec8">
                <title>Randomization, group allocation and concealment</title>
                <p id="Par15">The study used a parallel-group two-stage dosing regimen. In the first stage participants received low dose artesunate (LDA, 2.4 mg/kg) or placebo based on standard malaria dosing. Following an interim review of safety data participants in the second stage received high dose artesunate (HDA, 4.8 mg/kg) or placebo based on animal studies showing superior efficacy of HDA in reducing MODS after trauma haemorrhage [<xref ref-type="bibr" rid="CR15">15</xref>]. Participants were assigned to artesunate or placebo (2:1 ratio) using a random block-size randomization method. The randomization algorithm was generated by the trial statistician and validated by an external statistician. Sealed randomization cards were manufactured by an independent provider and opened sequentially by a study investigator after the decision to randomize a participant. Allocations were concealed from the participant, clinical team and investigating team collecting outcomes data. Due to the requirement to inspect drug re-constitution visually, the investigator who administered the intervention was not blind to treatment allocation.</p>
              </sec>
              <sec id="Sec9">
                <title>Assessments</title>
                <p id="Par16">Participants were screened for eligibility upon arrival to the resuscitation room. Their medical and trauma history was reviewed, and a pregnancy test obtained for women of childbearing age. After eligibility confirmation and consent, baseline vital signs and blood gases were measured, and the intervention was dispensed according to the randomization sequence. Pharmacokinetic blood samples were drawn before intervention delivery and at 5min, 30min, 60min, 4h and 12h after administration. Blood samples for routine investigations were drawn at admission and days 1–7, 14, 21 and 28. Patient demographics, injury characteristics and treatments were recorded. Injury severity was estimated using injury severity score (ISS) [<xref ref-type="bibr" rid="CR32">32</xref>]. Sequential organ failure assessment (SOFA) scores [<xref ref-type="bibr" rid="CR33">33</xref>] were calculated daily from admission to 7 days. MODS was defined as any daily SOFA &gt; 5 [<xref ref-type="bibr" rid="CR2">2</xref>]. Outcomes and safety data were reviewed daily until 28 days. Outcomes were also reviewed at discharge and 90 days.</p>
              </sec>
              <sec id="Sec10">
                <title>Endpoints</title>
                <p id="Par17">The safety endpoint was the serious adverse event (SAE) rate in the first 28 days. The primary efficacy endpoint was the SOFA scale score at 48 h after admission. Secondary endpoints included: maximum SOFA; average SOFA (of days 3, 4 and 5) [<xref ref-type="bibr" rid="CR34">34</xref>]; combined time to composite organ failure resolution (CTCOFR) at 14 days [<xref ref-type="bibr" rid="CR35">35</xref>]; ventilator free days [<xref ref-type="bibr" rid="CR36">36</xref>]; hospital and critical care length of stay (LOS); acute lung injury (ALI) [<xref ref-type="bibr" rid="CR37">37</xref>]; acute kidney injury (AKI) [<xref ref-type="bibr" rid="CR38">38</xref>]; infection [<xref ref-type="bibr" rid="CR39">39</xref>]; prolonged (PR)MODS (SOFA &gt; 5 on day 7) [<xref ref-type="bibr" rid="CR2">2</xref>]; alive and free of MODS at 48 h; and mortality (28 days, discharge, 90 days).</p>
              </sec>
              <sec id="Sec11">
                <title>Sample size calculation</title>
                <p id="Par18">Primary efficacy analysis was on the per-protocol (PP) cohort. We chose a clinically meaningful reduction in 48 h SOFA as a fall of two points. At 2:1 randomization, the study required 70 intervention and 35 control subjects to detect this difference with 80% power (<italic>α</italic> = 0.05; <italic>σ</italic> = 3.43, <italic>t</italic>-test).</p>
              </sec>
              <sec id="Sec12">
                <title>Statistical analysis</title>
                <p id="Par19">Efficacy analyses were performed on PP and intention-to-treat (ITT) populations. The PP cohort included all patients randomized and treated according to the study protocol, whereas the ITT cohort included all patients randomized to their treatment allocation irrespective of whether they received the treatment. The safety analysis included all patients who received artesunate or placebo and was performed according to treatment received. Comparisons included all artesunate vs. placebo, LDA vs. placebo and HDA vs. placebo. Data are presented as median, mean and interquartile ranges (IQR) for continuous variables and numbers and percentages for categorical variables. Baseline characteristics and outcomes were compared using Mann–Whitney <italic>U</italic>-tests and Pearson Chi-squared tests. Confidence intervals (CI) on mean differences between group outcomes were estimated using non-parametric empirical bootstrap. Mortality was estimated using the Kaplan–Meier method. SAEs were analysed by number and type, and CIs were estimated for the difference in proportions of participants with one or more SAEs in each group [<xref ref-type="bibr" rid="CR40">40</xref>]. Routine bloods were examined for safety. Plasma concentrations of artesunate and its active metabolite, dihydroartemisinin, were analysed at the Mahidol Oxford Tropical Medicine Research Unit (Bangkok, Thailand) using a validated LC–MS/MS [<xref ref-type="bibr" rid="CR41">41</xref>] assay and presented graphically. The main analyses were done in SPSS (version 26) by JMS and validated by ARB using R (version 3.6.3).</p>
              </sec>
              <sec id="Sec13">
                <title>Exploratory post-hoc safety analyses</title>
                <p id="Par20">Post-hoc analyses were conducted to examine a potential association between artesunate and venous thromboembolism (VTE). VTE was classified as deep vein thrombosis (DVT), pulmonary embolism (PE) and ‘other’, which referred to any other thrombotic or embolic vascular event deemed significant by the study team and the drug monitoring committee (DMC). We recorded DVTs and PEs that were clinically diagnosed, but we did not specifically screen patients for VTE. We also determined if patients were commenced on daily prophylactic low molecular weight heparin (LMWH; tinzaparin 4500 units) within 48 h of admission. The relative risk (RR) of VTE between placebo and artesunate groups was compared using a Chi-squared test. Logistic regression was used to determine whether differences in baseline characteristics (gender, shock) or receipt of early LMWH contributed to higher numbers of SAEs and VTE in the artesunate group. We also compared coagulation values (international normalised ratio—INR, platelet count) and the proportion of coagulopathic patients in each group defined by an INR ≥ 1.3 [<xref ref-type="bibr" rid="CR42">42</xref>].</p>
              </sec>
              <sec id="Sec14">
                <title>Exploratory post-hoc efficacy analyses</title>
                <p id="Par21">Post-hoc linear regression was performed to determine whether imbalances in baseline characteristics (age, gender, ISS, base deficit—BD) contributed to differences in the primary outcome between the groups. We also conducted post-hoc subgroup analyses of outcomes in blunt and penetrating trauma cohorts.</p>
              </sec>
              <sec id="Sec15">
                <title>Drug monitoring committee and trial steering committee review</title>
                <p id="Par22">The DMC reviewed the SAE profile after recruitment of every 15 patients. There were no formal stopping rules due to difficulty in assigning causality to the intervention. Progress to the next stage of the trial depended on whether a meaningful difference in the safety profile was detected during the interim review. The DMC provided their report to the independent trial steering committee (TSC), who were responsible for recommending trial continuation.</p>
              </sec>
            </sec>
            <sec id="Sec16">
              <title>Results</title>
              <p id="Par23">Participant recruitment occurred between 21st March 2017 and 15th May 2019. Follow-up was completed by 10th August 2019. Recruitment was suspended between April 30th to September 29th 2017 (pending delivery of a new batch of diluent), and between 30th June and 14th November 2018 (pending the interim review outcome). The trial was halted after 90 patients were enrolled, following a DMC review of safety data.</p>
              <sec id="Sec17">
                <title>Study participants</title>
                <p id="Par24">During the recruitment period 211 trauma calls activated the MHP, from which 105 patients met eligibility criteria, and 90 were randomized to intervention or comparator groups (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). All patients, except those who subsequently declined consent (<italic>n</italic> = 5), were included in ITT analyses (<italic>n</italic> = 85) and all patients who received artesunate or placebo were included in safety analyses (<italic>n</italic> = 83). Seventy-five patients were evaluable for PP analysis after exclusions for protocol violations (<italic>n</italic> = 10).<fig id="Fig1"><label>Fig. 1</label><caption><p>CONSORT recruitment flow diagram. <italic>HDA</italic> high dose artesunate, <italic>ITT</italic> intention-to-treat, <italic>LDA</italic> low dose artesunate, <italic>MHP</italic> major hemorrhage protocol, <italic>PP</italic> per-protocol, <italic>TBI</italic> traumatic brain injury. <sup>a</sup>Trauma patient who activates the MHP. <sup>b</sup>Excluded before intervention given. <sup>c</sup>Excluded after intervention given. <sup>d</sup>LDA ITT analysis exclusions: declined consent = 4. <sup>e</sup>LDA safety analysis exclusions: did not receive intervention = 4. One participant was randomized to the placebo group but received LDA in error; they were analysed in the LDA safety analysis. <sup>f</sup>HDA ITT analysis exclusions: declined consent = 1. <sup>g</sup>HDA safety analysis exclusions: did not receive intervention = 2. <sup>h</sup>Placebo ITT analysis exclusions: none. <sup>i</sup>Placebo safety analysis exclusions: incorrect intervention = 1</p></caption><graphic xlink:href="134_2023_7135_Fig1_HTML" id="MO1"/></fig></p>
                <p id="Par25">The study cohort (Table <xref rid="Tab1" ref-type="table">1</xref>, PP population) was predominantly male (88%, 66/75) with a median age of 29 years (IQR 19–49) and 51% (38/75) had sustained penetrating injury. Participants were severely injured (median ISS 22), and in shock on admission (median BD 6.2). The artesunate group had a lower proportion of males (81% vs. 100% <italic>p</italic> = 0.016), lower admission Glasgow Coma Scores—GCS (median 14 vs. 15, <italic>p</italic> = 0.044) and higher admission BD values (median 9 vs. 4.7, <italic>p</italic> = 0.042) vs. placebo. Findings were similar in ITT and safety populations (Supplementary material 3 Tables 1 and 2). Plasma concentrations of artesunate and dihydroartemisinin were within the therapeutic range previously reported in malaria patients (Supplementary material 3 Fig. 1).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Per-protocol population baseline characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Statistic</th><th align="left">Placebo</th><th align="left">Artesunate (All)</th><th align="left"><italic>p</italic> value</th><th align="left">Artesunate (LD)</th><th align="left">Artesunate (HD)</th></tr></thead><tbody><tr><td align="left"><italic>N</italic></td><td align="left"/><td align="left">27</td><td align="left">48</td><td align="left">–</td><td align="left">31</td><td align="left">17</td></tr><tr><td align="left">Sex</td><td align="left">Male (%)</td><td align="left">27 (100)</td><td align="left">39 (81)</td><td align="left">0.016*<sup>a</sup></td><td align="left">25 (81)</td><td align="left">14 (82)</td></tr><tr><td align="left"/><td align="left">Total N</td><td align="left">27</td><td align="left">48</td><td align="left"/><td align="left">31</td><td align="left">17</td></tr><tr><td align="left">Age (y)</td><td align="left">Median (Mean)</td><td align="left">30 (36)</td><td align="left">29 (34)</td><td align="left">0.868</td><td align="left">29 (32)</td><td align="left">32 (38)</td></tr><tr><td align="left"/><td align="left">IQR</td><td align="left">18 to 54</td><td align="left">20 to 41</td><td align="left"/><td align="left">19 to 39</td><td align="left">23 to 49</td></tr><tr><td align="left"/><td align="left">Total N</td><td align="left">27</td><td align="left">48</td><td align="left"/><td align="left">31</td><td align="left">17</td></tr><tr><td align="left">Injury type</td><td align="left">Blunt (%)</td><td align="left">12 (44)</td><td align="left">25 (52)</td><td align="left">0.525<sup>a</sup></td><td align="left">17 (55)</td><td align="left">8 (47)</td></tr><tr><td align="left"/><td align="left">Total N</td><td align="left">27</td><td align="left">48</td><td align="left"/><td align="left">31</td><td align="left">17</td></tr><tr><td align="left">ISS</td><td align="left">Median (Mean)</td><td align="left">20 (21)</td><td align="left">22 (24)</td><td align="left">0.353</td><td align="left">25 (25)</td><td align="left">22 (22)</td></tr><tr><td align="left"/><td align="left">IQR</td><td align="left">9 to 34</td><td align="left">13 to 31</td><td align="left"/><td align="left">13 to 34</td><td align="left">14 to 27</td></tr><tr><td align="left"/><td align="left">Total N</td><td align="left">27</td><td align="left">48</td><td align="left"/><td align="left">31</td><td align="left">17</td></tr><tr><td align="left">Time to admission (min)</td><td align="left">Median (Mean)</td><td align="left">88 (80)</td><td align="left">71 (71)</td><td align="left">0.132</td><td align="left">74 (71)</td><td align="left">69 (70)</td></tr><tr><td align="left"/><td align="left">IQR</td><td align="left">55 to 102</td><td align="left">47 to 93</td><td align="left"/><td align="left">48 to 94</td><td align="left">46 to 90</td></tr><tr><td align="left"/><td align="left">Total N</td><td align="left">27</td><td align="left">48</td><td align="left"/><td align="left">31</td><td align="left">17</td></tr><tr><td align="left">GCS at admission</td><td align="left">Median (Mean)</td><td align="left">15 (13)</td><td align="left">14 (12)</td><td align="left">0.044</td><td align="left">14 (12)</td><td align="left">14 (13)</td></tr><tr><td align="left"/><td align="left">IQR</td><td align="left">14 to 15</td><td align="left">11 to 15</td><td align="left"/><td align="left">9 to 15</td><td align="left">12 to 15</td></tr><tr><td align="left"/><td align="left">Total N</td><td align="left">25</td><td align="left">46</td><td align="left"/><td align="left">30</td><td align="left">16</td></tr><tr><td align="left">HR (bpm) at admission</td><td align="left">Median (Mean)</td><td align="left">110 (108)</td><td align="left">114 (111)</td><td align="left">0.463</td><td align="left">118 (118)</td><td align="left">109 (101)</td></tr><tr><td align="left"/><td align="left">IQR</td><td align="left">88 to 123</td><td align="left">97 to 126</td><td align="left"/><td align="left">105 to 128</td><td align="left">79 to 123</td></tr><tr><td align="left"/><td align="left">Total N</td><td align="left">27</td><td align="left">44</td><td align="left"/><td align="left">28</td><td align="left">16</td></tr><tr><td align="left">Systolic BP (mmHg) at admission</td><td align="left">Median (Mean)</td><td align="left">89 (94)</td><td align="left">100 (97)</td><td align="left">0.639</td><td align="left">103 (99)</td><td align="left">90 (92)</td></tr><tr><td align="left"/><td align="left">IQR</td><td align="left">71 to 115</td><td align="left">71 to 112</td><td align="left"/><td align="left">76 to 114</td><td align="left">65 to 112</td></tr><tr><td align="left"/><td align="left">Total N</td><td align="left">26</td><td align="left">39</td><td align="left"/><td align="left">24</td><td align="left">15</td></tr><tr><td align="left">BD (mmol/L) at admission</td><td align="left">Median (Mean)</td><td align="left">4.7 (7)</td><td align="left">9 (9.8)</td><td align="left">0.042</td><td align="left">9.5 (9.8)</td><td align="left">8.7 (− 0.7)</td></tr><tr><td align="left"/><td align="left">IQR</td><td align="left">3.3 to 9.4</td><td align="left">4.9 to 12.8</td><td align="left"/><td align="left">4.9 to 13.1</td><td align="left">5 to 11.2</td></tr><tr><td align="left"/><td align="left">Total N</td><td align="left">27</td><td align="left">44</td><td align="left"/><td align="left">27</td><td align="left">17</td></tr><tr><td align="left">RBCs in 24 h</td><td align="left">Median (Mean)</td><td align="left">6 (8)</td><td align="left">5 (7)</td><td align="left">0.677</td><td align="left">6 (8)</td><td align="left">4 (6)</td></tr><tr><td align="left"/><td align="left">IQR</td><td align="left">4 to 8</td><td align="left">4 to 9</td><td align="left"/><td align="left">4 to 9</td><td align="left">1 to 10</td></tr><tr><td align="left"/><td align="left">Total N</td><td align="left">27</td><td align="left">48</td><td align="left"/><td align="left">31</td><td align="left">17</td></tr><tr><td align="left">Total blood products in 24 h</td><td align="left">Median (Mean)</td><td align="left">16 (20)</td><td align="left">13 (18)</td><td align="left">0.890</td><td align="left">15 (20)</td><td align="left">12 (16)</td></tr><tr><td align="left"/><td align="left">IQR</td><td align="left">10 to 19</td><td align="left">9 to 26</td><td align="left"/><td align="left">10 to 23</td><td align="left">7 to 29</td></tr><tr><td align="left"/><td align="left">Total N</td><td align="left">27</td><td align="left">48</td><td align="left"/><td align="left">31</td><td align="left">17</td></tr></tbody></table><table-wrap-foot><p><italic>p</italic>-value compares Placebo vs Artesunate (All); Mann Whitney <italic>U</italic> test unless <sup>a</sup>Pearson Chi-square test; *<italic>p</italic> &lt; 0.05</p><p><italic>BD</italic> base deficit, <italic>BP</italic> blood pressure, <italic>GCS</italic> Glasgow Coma Score, <italic>HD</italic> high dose, <italic>HR</italic> heart rate, <italic>ISS</italic> Injury Severity Score, <italic>LD</italic> low dose, <italic>RBC</italic> red blood cells</p></table-wrap-foot></table-wrap></p>
              </sec>
              <sec id="Sec18">
                <title>Safety endpoints</title>
                <p id="Par26">The total number of SAEs (Table <xref rid="Tab2" ref-type="table">2</xref>, Supplementary material 3 Table 3) was higher in the artesunate (vs. placebo) group (23 vs. 8), as was the proportion of patients who experienced an SAE; 31% vs.17% (17/54 vs. 5/29, relative risk—RR 1.8 [95% CI 0.8–4.4], <italic>p</italic> = 0.161). Further scrutiny showed a high proportion of SAEs in the artesunate group were due to VTE (48%, 11/23) vs. placebo (13%, 1/8). There were no differences in mortality (Supplementary material 3 Fig. 2c, Supplementary material 3 Table 4a and b). Routine blood tests did not identify any immediate safety concerns (Supplementary material 3 Appendix Tables 1–10).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Safety population serious adverse events to 28 days summary report</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Statistic</th><th align="left">Placebo</th><th align="left">Artesunate (Total)</th><th align="left">% Difference (95% CI)</th></tr></thead><tbody><tr><td align="left">Patients, <italic>N</italic></td><td align="left">29</td><td align="left">54</td><td align="left"/></tr><tr><td align="left">Total number of SAEs, <italic>N</italic></td><td align="left">8</td><td align="left">23</td><td align="left"/></tr><tr><td align="left">Patients with one or more SAEs, <italic>N</italic> (%)</td><td align="left">5 (17)</td><td align="left">17 (31)</td><td align="left">14% (− 8 to 32)</td></tr><tr><td align="left" colspan="4">Type of SAE, <italic>N</italic> (% of SAEs)</td></tr><tr><td align="left"> Infection</td><td align="left">2 (25)</td><td align="left">3 (13)</td><td align="left"/></tr><tr><td align="left"> Thromboembolic</td><td align="left">1 (13)</td><td align="left">11 (48)</td><td align="left"/></tr><tr><td align="left"> Ischemic injury</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left"/></tr><tr><td align="left"> Organ failure</td><td align="left">1 (13)</td><td align="left">1 (4)</td><td align="left"/></tr><tr><td align="left"> Acute kidney injury</td><td align="left">1 (13)</td><td align="left">2 (9)</td><td align="left"/></tr><tr><td align="left"> Acute lung injury</td><td align="left">1 (13)</td><td align="left">0 (0)</td><td align="left"/></tr><tr><td align="left"> New onset major bleed</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left"/></tr><tr><td align="left"> Cardiac</td><td align="left">1 (13)</td><td align="left">1 (4)</td><td align="left"/></tr><tr><td align="left"> Neurological</td><td align="left">1 (13)</td><td align="left">1 (4)</td><td align="left"/></tr><tr><td align="left"> Other</td><td align="left">0 (0)</td><td align="left">4 (17)</td><td align="left"/></tr></tbody></table><table-wrap-foot><p><italic>CI</italic> Confidence Interval, <italic>SAE</italic> Serious Adverse Event</p></table-wrap-foot></table-wrap></p>
              </sec>
              <sec id="Sec19">
                <title>Early trial termination</title>
                <p id="Par27">Safety data were reviewed by the DMC after recruitment of 15, 30, 51 (interim analysis), 66 and 79 patients. At the interim review, 14 SAEs were recorded, and of these, four were related to VTE and occurred in the same treatment group. The DMC requested a separate analysis of VTE in subsequent reports. After the final DMC review, the trial was suspended because of further data supporting an imbalance in VTE frequency between treatment groups. A second ad hoc interim analysis (total 90 patients) was requested by the TSC and compiled by the trial statistician (ARB). Based on this report, the TSC advised early termination of the trial due to a potentially increased VTE risk in the artesunate group, and insufficient evidence supporting superiority of artesunate in trauma hemorrhage, unlikely to be altered by full sample recruitment.</p>
              </sec>
              <sec id="Sec20">
                <title>Primary efficacy endpoint</title>
                <p id="Par28">There was no statistically significant difference in 48 h SOFA in the PP population between study arms (median 5.5 vs. 4, <italic>p</italic> = 0.303). This included when LDA (median 6 vs. 4, <italic>p</italic> = 0.411) and HDA (median 5 vs. 4, <italic>p</italic> = 0.326) arms were analysed separately (Table <xref rid="Tab3" ref-type="table">3</xref>). Findings were similar in ITT analyses (Supplementary material 3 Table 7a).<table-wrap id="Tab3"><label>Table 3</label><caption><p>Safety population venous thromboembolism detailed report (post-hoc analysis)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Statistic</th><th align="left">Placebo</th><th align="left">Artesunate (Total)</th><th align="left"><italic>p</italic> value</th><th align="left">Artesunate (LD)</th><th align="left">Artesunate (HD)</th></tr></thead><tbody><tr><td align="left">Total patients</td><td align="left"><italic>N</italic></td><td align="left">29</td><td align="left">54</td><td align="left"/><td align="left">34</td><td align="left">20</td></tr><tr><td align="left">Patients with VTE</td><td align="left"><italic>N</italic> (%)</td><td align="left">1 (3)</td><td align="left">9 (17)</td><td align="left">0.078</td><td align="left">8 (24)</td><td align="left">1 (5)</td></tr><tr><td align="left">Total VTE Events</td><td align="left"><italic>N</italic></td><td align="left">1</td><td align="left">11</td><td align="left"/><td align="left">9</td><td align="left">2</td></tr><tr><td align="left">Total PE</td><td align="left"><italic>N</italic> (%)</td><td align="left">1 (100)</td><td align="left">4 (36)</td><td align="left"/><td align="left">3 (33)</td><td align="left">1 (50)</td></tr><tr><td align="left">Total DVT</td><td align="left"><italic>N</italic> (%)</td><td align="left">0</td><td align="left">4 (36)</td><td align="left"/><td align="left">4 (44)</td><td align="left">0</td></tr><tr><td align="left">Other*</td><td align="left"><italic>N</italic> (%)</td><td align="left">0</td><td align="left">3 (27)</td><td align="left"/><td align="left">2 (22)</td><td align="left">1 (50)</td></tr><tr><td align="left">Day of first VTE</td><td align="left">Median (mean)</td><td align="left">11 (11)</td><td align="left">5 (6)</td><td align="left"/><td align="left">7 (6)</td><td align="left">3 (3)</td></tr><tr><td align="left"/><td align="left">IQR</td><td align="left">–</td><td align="left">1 to 8</td><td align="left"/><td align="left">1 to 10</td><td align="left">3 to 3</td></tr><tr><td align="left"/><td align="left">Missing</td><td align="left">0</td><td align="left">0</td><td align="left"/><td align="left">0</td><td align="left">0</td></tr></tbody></table><table-wrap-foot><p><italic>p</italic> value compares Placebo vs Artesunate (Total); Chi squared test; <italic>p</italic> &lt; 0.05</p><p><italic>HD</italic> high dose, <italic>LD</italic> low dose, <italic>VTE</italic> venous thromboembolism</p><p><sup>*</sup>Includes: Right middle cerebral artery infarction (LD artesunate); Embolism at site of injury detected during surgical repair (LD artesunate); Occlusive expansion clot SMV/IMV portal vein confluence (HD artesunate)</p></table-wrap-foot></table-wrap></p>
              </sec>
              <sec id="Sec21">
                <title>Secondary endpoints</title>
                <p id="Par29">There was little difference in the secondary endpoints between artesunate and placebo groups in both PP (Table <xref rid="Tab4" ref-type="table">4</xref>, Fig. <xref rid="Fig2" ref-type="fig">2</xref>, and Supplementary material 3 Fig. 2a) and ITT analyses (Supplementary material 3 Table 7b and Supplementary material 3 Fig. 2b). Overall, 68% (51/75) of patients developed MODS and 21% (16/75) developed PRMODS, with similar proportions in artesunate vs. placebo groups (MODS: 69% vs. 67%, PRMODS: 21% vs. 22%). Maximum SOFA scores were similar (median 10 vs. 9), while analysis of trajectories showed average SOFA scores were initially higher in the artesunate group but became similar between days 5 and 7 (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). Despite this, critical care usage was similar, and non-significantly lower in the artesunate group (median 8 vs. 11 days, <italic>p</italic> = 0.736). The overall 90-days mortality rates were low (4%, 3/75) with no differences between the groups (artesunate, 4%, 2/48 vs. placebo, 4%, 1/27; <italic>p</italic> = 0.992).<table-wrap id="Tab4"><label>Table 4</label><caption><p>Per-protocol outcome measures</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Statistic</th><th align="left">Placebo</th><th align="left">Artesunate (All)</th><th align="left">Mean Difference (95% CI)</th><th align="left"><italic>p</italic> value</th><th align="left">Artesunate (LD)</th><th align="left"><italic>p</italic> value</th><th align="left">Artesunate (HD)</th><th align="left"><italic>p</italic> value</th></tr></thead><tbody><tr><td align="left"><italic>N</italic></td><td align="left"/><td align="left">27</td><td align="left">48</td><td align="left"/><td align="left"/><td align="left">31</td><td align="left"/><td align="left">17</td><td align="left"/></tr><tr><td align="left" colspan="2"><bold>Primary outcome</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">48 h SOFA</td><td align="left">Median (Mean)</td><td align="left">4 (5.3)</td><td align="left">5.5 (6.4)</td><td align="left">− 1.1 (− 3.1 to 0.9)</td><td align="left">0.303</td><td align="left">6 (6.3)</td><td align="left">0.411</td><td align="left">5 (6.7)</td><td align="left">0.326</td></tr><tr><td align="left"/><td align="left">IQR</td><td align="left">2 to 8</td><td align="left">2.5 to 10.5</td><td align="left"/><td align="left"/><td align="left">2 to 11</td><td align="left"/><td align="left">3 to 10</td><td align="left"/></tr><tr><td align="left"/><td align="left">Total <italic>N</italic></td><td align="left">27</td><td align="left">48</td><td align="left"/><td align="left"/><td align="left">31</td><td align="left"/><td align="left">17</td><td align="left"/></tr><tr><td align="left" colspan="2"><bold>Secondary outcomes</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Max SOFA</td><td align="left">Median (Mean)</td><td align="left">9 (7.9)</td><td align="left">10 (9.1)</td><td align="left">− 1.2 (− 3.1 to 0.7)</td><td align="left">0.252</td><td align="left">10 (9)</td><td align="left">0.313</td><td align="left">10 (9.3)</td><td align="left">0.345</td></tr><tr><td align="left"/><td align="left">IQR</td><td align="left">4 to 10</td><td align="left">5 to 12.5</td><td align="left"/><td align="left"/><td align="left">5 to 12</td><td align="left"/><td align="left">4 to 13</td><td align="left"/></tr><tr><td align="left"/><td align="left">Total <italic>N</italic></td><td align="left">27</td><td align="left">48</td><td align="left"/><td align="left"/><td align="left">31</td><td align="left"/><td align="left">17</td><td align="left"/></tr><tr><td align="left">Mean SOFA</td><td align="left">Median (Mean)</td><td align="left">3.3 (5.3)</td><td align="left">5.9 (6.2)</td><td align="left">− 0.9 (− 2.9 to 1.1)</td><td align="left">0.536</td><td align="left">5 (6)</td><td align="left">0.569</td><td align="left">6.3 (6.5)</td><td align="left">0.638</td></tr><tr><td align="left"/><td align="left">IQR</td><td align="left">2 to 8.3</td><td align="left">2.3 to 9</td><td align="left"/><td align="left"/><td align="left">2.5 to 9</td><td align="left"/><td align="left">1.8 to 8.8</td><td align="left"/></tr><tr><td align="left"/><td align="left">Total <italic>N</italic></td><td align="left">27</td><td align="left">48</td><td align="left"/><td align="left"/><td align="left">31</td><td align="left"/><td align="left">17</td><td align="left"/></tr><tr><td align="left">PRMODS</td><td align="left"><italic>N</italic> (%)</td><td align="left">6 (22)</td><td align="left">10 (21)</td><td align="left">–</td><td align="left">0.859<sup>a,b</sup></td><td align="left">6 (19)</td><td align="left">0.780<sup>a,b</sup></td><td align="left">4 (24)</td><td align="left">0.973<sup>a,b</sup></td></tr><tr><td align="left"/><td align="left">Died &lt; 7d (%)</td><td align="left">1 (4)</td><td align="left">1 (2)</td><td align="left"/><td align="left"/><td align="left">1 (3)</td><td align="left"/><td align="left">0 (0)</td><td align="left"/></tr><tr><td align="left"/><td align="left">Total N</td><td align="left">27</td><td align="left">48</td><td align="left"/><td align="left"/><td align="left">31</td><td align="left"/><td align="left">17</td><td align="left"/></tr><tr><td align="left">CTCOFR14 score</td><td align="left">Median (Mean)</td><td align="left">4 (7.3)</td><td align="left">5 (6.8)</td><td align="left">0.5 (− 2.6 to 3.6)</td><td align="left">0.640</td><td align="left">6 (7)</td><td align="left">0.701</td><td align="left">4 (6.5)</td><td align="left">0.667</td></tr><tr><td align="left"/><td align="left">IQR</td><td align="left">1 to 15</td><td align="left">0 to 15</td><td align="left"/><td align="left"/><td align="left">0 to 15</td><td align="left"/><td align="left">1 to 13</td><td align="left"/></tr><tr><td align="left"/><td align="left">Total <italic>N</italic></td><td align="left">27</td><td align="left">48</td><td align="left"/><td align="left"/><td align="left">31</td><td align="left"/><td align="left">17</td><td align="left"/></tr><tr><td align="left">VFD</td><td align="left">Median (Mean)</td><td align="left">26 (19.7)</td><td align="left">25 (21.1)</td><td align="left">− 1.4 (− 6.2 to 3.2)</td><td align="left">0.591</td><td align="left">25 (20.3)</td><td align="left">0.768</td><td align="left">26 (22.5)</td><td align="left">0.474</td></tr><tr><td align="left"/><td align="left">IQR</td><td align="left">12 to 28</td><td align="left">16 to 28</td><td align="left"/><td align="left"/><td align="left">14 to 28</td><td align="left"/><td align="left">19 to 28</td><td align="left"/></tr><tr><td align="left"/><td align="left">Total <italic>N</italic></td><td align="left">27</td><td align="left">48</td><td align="left"/><td align="left"/><td align="left">31</td><td align="left"/><td align="left">17</td><td align="left"/></tr><tr><td align="left">CC LOS, days</td><td align="left">Median (Mean)</td><td align="left">11 (18.1)</td><td align="left">8 (11.8)</td><td align="left">6.3 (− 2.1 to 16.2)</td><td align="left">0.736</td><td align="left">8 (11.5)</td><td align="left">0.870</td><td align="left">9 (12.5)</td><td align="left">0.629</td></tr><tr><td align="left"/><td align="left">IQR</td><td align="left">3 to 24</td><td align="left">5 to 18.5</td><td align="left"/><td align="left"/><td align="left">5 to 19)</td><td align="left"/><td align="left">3 to 18</td><td align="left"/></tr><tr><td align="left"/><td align="left">Total <italic>N</italic></td><td align="left">27</td><td align="left">48</td><td align="left"/><td align="left"/><td align="left">31</td><td align="left"/><td align="left">17</td><td align="left"/></tr><tr><td align="left">Hospital LOS, days</td><td align="left">Median (Mean)</td><td align="left">28 (34.2)</td><td align="left">25 (33.2)</td><td align="left">1 (− 12.2 to 14.6)</td><td align="left">0.770</td><td align="left">25 (32)</td><td align="left">0.779</td><td align="left">26 (35.4)</td><td align="left">0.838</td></tr><tr><td align="left"/><td align="left">IQR</td><td align="left">10 to 52</td><td align="left">9 to 42</td><td align="left"/><td align="left"/><td align="left">9 to 43</td><td align="left"/><td align="left">9 to 41</td><td align="left"/></tr><tr><td align="left"/><td align="left">Total <italic>N</italic></td><td align="left">27</td><td align="left">48</td><td align="left"/><td align="left"/><td align="left">31</td><td align="left"/><td align="left">17</td><td align="left"/></tr><tr><td align="left">Infection</td><td align="left"><italic>N</italic> (%)</td><td align="left">11 (41)</td><td align="left">19 (40)</td><td align="left">–</td><td align="left">0.922<sup>a</sup></td><td align="left">11 (35)</td><td align="left">0.681<sup>a</sup></td><td align="left">8 (47)</td><td align="left">0.680<sup>a</sup></td></tr><tr><td align="left"/><td align="left">Total <italic>N</italic></td><td align="left">27</td><td align="left">48</td><td align="left"/><td align="left"/><td align="left">31</td><td align="left"/><td align="left">17</td><td align="left"/></tr><tr><td align="left">ALI</td><td align="left">ALI Mild + (%)</td><td align="left">20 (74)</td><td align="left">31 (65)</td><td align="left">–</td><td align="left">0.398<sup>a</sup></td><td align="left">20 (65)</td><td align="left">0.433<sup>a</sup></td><td align="left">11 (65)</td><td align="left">0.507<sup>a</sup></td></tr><tr><td align="left"/><td align="left">Total <italic>N</italic></td><td align="left">27</td><td align="left">48</td><td align="left"/><td align="left"/><td align="left">31</td><td align="left"/><td align="left">17</td><td align="left"/></tr><tr><td align="left">AKI</td><td align="left">AKI Injury + (%)</td><td align="left">20 (74)</td><td align="left">40 (83)</td><td align="left">–</td><td align="left">0.336<sup>a</sup></td><td align="left">25 (81)</td><td align="left">0.549<sup>a</sup></td><td align="left">15 (88)</td><td align="left">0.257<sup>a</sup></td></tr><tr><td align="left"/><td align="left">Total <italic>N</italic></td><td align="left">27</td><td align="left">48</td><td align="left"/><td align="left"/><td align="left">31</td><td align="left"/><td align="left">17</td><td align="left"/></tr><tr><td align="left">Mortality</td><td align="left">28d (%)</td><td align="left">1 (4)</td><td align="left">2 (4)</td><td align="left">–</td><td align="left">0.922<sup>a</sup></td><td align="left">2 (7)</td><td align="left">0.637<sup>a</sup></td><td align="left">0</td><td align="left">0.422<sup>a</sup></td></tr><tr><td align="left"/><td align="left">Discharge (%)</td><td align="left">1 (4)</td><td align="left">2 (4)</td><td align="left">–</td><td align="left">0.922<sup>a</sup></td><td align="left">2 (7)</td><td align="left">0.637<sup>a</sup></td><td align="left">0</td><td align="left">0.422<sup>a</sup></td></tr><tr><td align="left"/><td align="left">90d (%)</td><td align="left">1 (4)</td><td align="left">2 (4)</td><td align="left">–</td><td align="left">0.922<sup>a</sup></td><td align="left">2 (7)</td><td align="left">0.637<sup>a</sup></td><td align="left">0</td><td align="left">0.422<sup>a</sup></td></tr><tr><td align="left"/><td align="left">Total <italic>N</italic></td><td align="left">27</td><td align="left">48</td><td align="left"/><td align="left"/><td align="left">31</td><td align="left"/><td align="left">17</td><td align="left"/></tr><tr><td align="left">Alive and MODS free 48 h</td><td align="left"><italic>N</italic> (%)</td><td align="left">18 (67)</td><td align="left">24 (50)</td><td align="left">–</td><td align="left">0.163<sup>a</sup></td><td align="left">15 (48)</td><td align="left">0.161<sup>a</sup></td><td align="left">9 (53)</td><td align="left">0.363<sup>a</sup></td></tr><tr><td align="left"/><td align="left">Total <italic>N</italic></td><td align="left">27</td><td align="left">48</td><td align="left"/><td align="left"/><td align="left">31</td><td align="left"/><td align="left">17</td><td align="left"/></tr></tbody></table><table-wrap-foot><p><italic>p</italic> values compare Placebo vs Artesunate (All), Placebo vs Artesunate (LD) and Placebo vs Artesunate (HD); Mann Whitney <italic>U</italic> test unless <sup>a</sup>Pearson Chi-squared test; <sup>b</sup>Comparison excludes deaths &lt; 7 days; <italic>p</italic> &lt; 0.05</p><p>Mean SOFA refers to the mean SOFA score between and including days 3 to 5</p><p><italic>AKI</italic> acute kidney injury, <italic>CC</italic> critical care, <italic>CI</italic> confidence interval, <italic>CTCOFR14</italic> Composite Time to Complete Organ Failure Resolution at 14 days, <italic>HD</italic> high dose, <italic>HR</italic> heart rate, <italic>LD</italic> low dose, <italic>LOS</italic> length of stay, <italic>MODS</italic> multiple organ dysfunction syndrome, <italic>PRMODS</italic> prolonged MODS, <italic>SOFA</italic> Sequential Organ Failure Assessment score, <italic>TBI</italic> traumatic brain injury</p></table-wrap-foot></table-wrap><fig id="Fig2"><label>Fig. 2</label><caption><p>Mean SOFA scores (line) and standard error (bar) by day of admission for artesunate and placebo groups (per-protocol population). <bold>a</bold> All patients (placebo, <italic>n</italic> = 27; artsunate, <italic>n</italic> = 48); <bold>b</bold> patients with multiple organ dysfunction syndrome (MODS)(placebo, <italic>n</italic> = 18; artesunate, <italic>n</italic> = 33). MODS is defined as a SOFA score &gt; 5 during days 0 to 7 after admission</p></caption><graphic xlink:href="134_2023_7135_Fig2_HTML" id="MO2"/></fig></p>
              </sec>
              <sec id="Sec22">
                <title>Exploratory post-hoc safety results</title>
                <p id="Par30">Post-hoc analysis to examine the potential association between artesunate and VTE (Table <xref rid="Tab3" ref-type="table">3</xref>) found the proportion of patients with VTE was non-significantly higher in the artesunate group; 17% vs. 3% (9/54 vs. 1/29, RR 4.8 [95% CI 0.6–36.3], <italic>p</italic> = 0.078). However, potentially fewer patients in the artesunate group received prophylactic LMWH within 48 h of admission; 35% vs. 53% (18/51 vs. 15/28, RR 0.7 [95% CI 0.4–1.1], <italic>p</italic> = 0.115). Binary logistic regression examining the effects of group imbalances on SAE and VTE rates (Supplementary material 3 Table 5) showed no effect of treatment group on the odds ratio (OR) of SAE or VTE; however, early prophylactic LMWH was associated with a reduced OR of SAE in this model (OR 0.248, <italic>p</italic> = 0.049). These analyses are limited by the small sample size. Examination of available coagulation parameters from admission to day 28 (Supplementary material 3, Table 6) showed patients in the artesunate group had a higher median INR values on day 1 (1.2 vs. 1.1; <italic>p</italic> = 0.012) and day 2 (1.2 vs. 1.1; <italic>p</italic> = 0.036), and lower platelet counts on day 2 (Day 2, 91 vs 122; <italic>p</italic> = 0.011) compared with the placebo group. There were non-significantly higher proportions of coagulopathic patients in the artesunate group on day 1 (33%, 16/48 vs. 13%, 3/23, <italic>p</italic> = 0.071) and day 2 (40%, 18/45 vs. 21%, 5/23, <italic>p</italic> = 0.123), despite similar proportions on admission (28%, 13/46 vs. 26%, 7/26, <italic>p</italic> = 0.786).</p>
              </sec>
              <sec id="Sec23">
                <title>Exploratory post-hoc efficacy results</title>
                <p id="Par31">Post-hoc multiple regression examining the effects of imbalances in baseline characteristics on the primary outcome (Supplementary material 3 Table 8) found independent effects of age, shock, and ISS on the 48 h SOFA score, but the observed adjusted effect of treatment was unchanged (48 h SOFA, <italic>β</italic> 0.34, CI − 1.4 to 2.1, <italic>p</italic> = 0.698). A post-hoc subgroup analysis of blunt and penetrating injury did not reveal any differences in efficacy or safety outcomes (Supplementary material 3 Tables 9a &amp; b).</p>
              </sec>
            </sec>
            <sec id="Sec24">
              <title>Discussion</title>
              <p id="Par32">The TOP-ART blinded placebo-controlled randomized clinical trial evaluated the safety and efficacy of intravenous artesunate in patients with severe trauma hemorrhage. The trial was terminated early because of safety concerns, with a potential imbalance of VTE rates and lack of evidence of treatment efficacy.</p>
              <p id="Par33">The reasons for the potentially increased VTE frequency in the artesunate group are not explained by this study. Artesunate has been used extensively in critically ill malaria patients over the past two decades without adverse effects, and to our knowledge no previous studies show an association between VTE and artesunate. VTE has a known association with shock and coagulopathy in trauma populations [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>], and the risk increases in the absence of prophylactic LMWH [<xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. It is possible that the more profound shock in the artesunate group, coupled with reduced rates of early thromboprophylaxis may partially explain the difference in post-treatment VTE events. Higher rates of early coagulation abnormality in the artesunate group may also have contributed to the increase in VTE, although it is not clear whether these differences in coagulation are related to artesunate or to the degree of shock on admission<italic>.</italic> VTE prevalence in placebo recipients was also low (3%). Further studies are required to clarify whether artesunate increases VTE in trauma hemorrhage or whether the result is spurious.</p>
              <p id="Par34">Artesunate was well positioned as a potentially effective therapeutic agent for post-injury MODS. Our pre-clinical research suggested that artesunate attenuated the severity of organ dysfunction after trauma hemorrhage and appeared to ameliorate maladaptive immune responses to injury by promoting cell survival pathways while inhibiting pro-inflammatory pathways [<xref ref-type="bibr" rid="CR15">15</xref>]. These findings were supported by human transcriptomic studies showing upregulation of pro-inflammatory signaling pathways in critically injured patients [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR47">47</xref>], and enrichment of pathways associated with cell survival and death (e.g., apoptosis, necrosis) in those with MODS [<xref ref-type="bibr" rid="CR17">17</xref>]. Our study design, with a defined cohort of patients at high risk of MODS, early therapeutic administration and clinically validated endpoints, aimed to address issues in previous human trauma trials of organ protective agents [<xref ref-type="bibr" rid="CR5">5</xref>]. Our final patient cohort’s incidence and severity of MODS is in line with our original projections for study design and sample size estimate. Despite this we did not identify any evidence of efficacy for artesunate in this indication.</p>
              <p id="Par35">The small sample size of the PP population led to imbalances between intervention and placebo groups. In particular, patients in the artesunate arm were substantially more shocked on admission, and this is known to be a key driver of MODS [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. Post-hoc analyses adjusting for shock and other baseline factors did not indicate a treatment effect, although these were limited by the sample size. The artesunate arm also had a very high proportion of penetrating trauma (51%), a group thought to have potentially different injury responses [<xref ref-type="bibr" rid="CR48">48</xref>] and which were excluded from our previous human transcriptomic analyses [<xref ref-type="bibr" rid="CR17">17</xref>]. However, post-hoc subgroup analyses did not reveal any differences in outcomes between blunt and penetrating trauma cohorts. Our cohort also had comparably low late mortality (4%) considering the degree of shock and injury severity on admission [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. While the low mortality may be explained by the exclusion of patients expected to die within the first 48 h, the cohort may not fully represent the total trauma population at risk of MODS and its consequences.</p>
              <p id="Par36">The immune response to trauma is complex, and the types of response that pre-dispose patients to MODS remain incompletely understood. The immunological pathways targeted by artesunate may not alter the course of MODS in human trauma patients. Alternatively, the dose and/or timing of artesunate used in our study may not be sufficient to achieve a therapeutic effect in human trauma patients. Our PK/PD analyses showed participants given a 2.4 mg/kg or 4.8 mg/kg bolus of artesunate had plasma levels within the therapeutic range for malaria treatment. However, animal models showed a dose-dependent relationship for artesunate benefit so a higher target range, or repeat dosing, may be required to achieve efficacy and impact upon organ dysfunction in human trauma. Future studies that interrogate biobank data in this cohort may provide further insight as to whether artesunate impacts on the inflammatory response in humans, while not affecting organ dysfunction as measured by the SOFA score. Finally, the clinical characterization of MODS is evolving [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR49">49</xref>] and it is possible that artesunate may only have efficacy against specific forms of MODS. Future research that matches underlying cell pathways to different clinical forms of MODS may enable more targeted patient and endpoint selection.</p>
              <p id="Par37">There are several limitations to this study. First, the trial was terminated early and did not reach full recruitment, limiting the power and precision of the primary end-point assessment. While the results did not convincingly demonstrate a benefit for the treatment, it is possible that one might still exist on the primary endpoint. However, the 95% CI did not support the presence of a clinically significant reduction in the 48 h SOFA with treatment, and the mean scores were higher overall in the treatment arm. Therefore, at the time of stopping the trial there was no signal to suggest a clinically meaningful benefit of treatment. Second, despite randomization, there were imbalances in the baseline characteristics between treatment groups, which affect group comparisons for both efficacy and VTE. The placebo group only included male participants and therefore results are most applicable for a male trauma population. Lastly, our study was not powered to detect differences in VTE rates between the groups. Future analyses that compare MODS and VTE outcomes between our dataset and matched cohorts from existing datasets (e.g., ACIT-2 [<xref ref-type="bibr" rid="CR50">50</xref>]) might provide further insight.</p>
              <p id="Par38">In this study of critically injured trauma patients with major hemorrhage, artesunate did not improve organ dysfunction and was potentially associated with an increased VTE risk. Future studies that focus on immune responses to injury and associated clinical forms of MODS may elucidate the reasons for this and facilitate identification of alternative pharmaceutical agents that attenuate MODS in trauma hemorrhage.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Information</title>
              <sec id="Sec25">
                <p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="134_2023_7135_MOESM1_ESM.pdf"><caption><p>Supplementary file1 (PDF 982 KB)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="134_2023_7135_MOESM2_ESM.pdf"><caption><p>Supplementary file2 (PDF 955 KB)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="134_2023_7135_MOESM3_ESM.docx"><caption><p>Supplementary file3 (DOCX 9364 KB)</p></caption></media></supplementary-material></p>
              </sec>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn>
                <p>
                  <bold>Publisher's Note</bold>
                </p>
                <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
              </fn>
              <fn>
                <p>Christoph Thiemermann and Karim Brohi are joint last author.</p>
              </fn>
            </fn-group>
            <ack>
              <title>Acknowledgements</title>
              <p>The authors would like to thank Col Brian Smith (U.S. Army Medical Materiel Development Activity) for providing phase I data for the Investigator Brochure; Sanofi for providing the Investigational Medicinal Product Dossier and confidential data to the Medicines and Healthcare products Regulation Authority; and Sigma Tau (now Alfa Wassermann Spa) for provision of Good Manufacturing Practice artesunate free of charge. We would like to acknowledge the contributions of trial research assistants Ayoyemi Macauly and Haya Akkad, and the trauma research fellows at the Centre for Trauma Sciences who recruited study participants and collected follow-up data.</p>
            </ack>
            <notes notes-type="author-contribution">
              <title>Author contributions</title>
              <p>The study was conceived by CT and KB. Methods were developed by JMS, CR, ARB, JT, NW, CT, and KB. Data acquisition was performed by JMS, JR, LA, and CR. The formal analysis was by JMS and ARB. The first draft of the manuscript was written by JMS, and it was reviewed and edited by ARB, JT, NW, KB and CT. All authors commented on previous versions of the manuscript and read and approved the final manuscript. Funding acquisition was by CT.</p>
            </notes>
            <notes notes-type="funding-information">
              <title>Funding</title>
              <p>This research was funded by the Wellcome Trust (Grant Reference Number: 101012/Z/13/Z) and Department of Health (Grant Reference Number: HICFR7405).</p>
            </notes>
            <notes notes-type="data-availability">
              <title>Data availability</title>
              <p>The data that support the findings of this trial are available from the corresponding author (JMS) upon reasonable request.</p>
            </notes>
            <notes>
              <title>Declarations</title>
              <notes id="FPar1" notes-type="COI-statement">
                <title>Conflicts of interest</title>
                <p id="Par39">The authors declare they have no conflict of interest, including financial interests, activities, relationships, and affiliations in relation with the TOP-ART Trial.</p>
              </notes>
              <notes id="FPar2">
                <title>Ethical approval</title>
                <p id="Par40">The trial was authorized by the Medicines and Healthcare products Regulation Authority (ref: 21313/0052/001-0001) on the 22nd January 2016 and approved by London City and East Research Ethics Committee (reference: 16/LO/003) on 11th March 2016. The trial was registered prospectively with the EU Clinical Trials Register (Identifier 2015-000301-40) and the ISRCTN (Identifier 15731357) on the 28th August 2015.</p>
              </notes>
              <notes id="FPar3">
                <title>Consent to participate</title>
                <p id="Par41">The trial was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants or, in cases of impaired capacity, their closest relative or appropriate representative.</p>
              </notes>
            </notes>
            <ref-list id="Bib1">
              <title>References</title>
              <ref id="CR1">
                <label>1.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cole</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Gillespie</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Vulliamy</surname>
                      <given-names>P</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Multiple organ dysfunction after trauma</article-title>
                  <source>Br J Surg</source>
                  <year>2020</year>
                  <volume>107</volume>
                  <fpage>402</fpage>
                  <lpage>412</lpage>
                  <pub-id pub-id-type="doi">10.1002/bjs.11361</pub-id>
                  <?supplied-pmid 31691956?>
                  <pub-id pub-id-type="pmid">31691956</pub-id>
                </element-citation>
              </ref>
              <ref id="CR2">
                <label>2.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Shepherd</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Cole</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Brohi</surname>
                      <given-names>K</given-names>
                    </name>
                  </person-group>
                  <article-title>Contemporary patterns of multiple organ dysfunction syndrome in trauma</article-title>
                  <source>Shock</source>
                  <year>2017</year>
                  <volume>47</volume>
                  <fpage>429</fpage>
                  <lpage>435</lpage>
                  <pub-id pub-id-type="doi">10.1097/SHK.0000000000000779</pub-id>
                  <?supplied-pmid 27798537?>
                  <pub-id pub-id-type="pmid">27798537</pub-id>
                </element-citation>
              </ref>
              <ref id="CR3">
                <label>3.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ulvik</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Kvåle</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Wentzel-Larsen</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Flaatten</surname>
                      <given-names>H</given-names>
                    </name>
                  </person-group>
                  <article-title>Multiple organ failure after trauma affects even long-term survival and functional status</article-title>
                  <source>Crit Care</source>
                  <year>2007</year>
                  <volume>11</volume>
                  <fpage>R95</fpage>
                  <pub-id pub-id-type="doi">10.1186/cc6111</pub-id>
                  <?supplied-pmid 17784940?>
                  <pub-id pub-id-type="pmid">17784940</pub-id>
                </element-citation>
              </ref>
              <ref id="CR4">
                <label>4.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sauaia</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Moore</surname>
                      <given-names>EE</given-names>
                    </name>
                    <name>
                      <surname>Johnson</surname>
                      <given-names>JL</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Temporal trends of postinjury multiple-organ failure</article-title>
                  <source>J Trauma Acute Care Surg</source>
                  <year>2014</year>
                  <volume>76</volume>
                  <fpage>582</fpage>
                  <lpage>593</lpage>
                  <pub-id pub-id-type="doi">10.1097/TA.0000000000000147</pub-id>
                  <?supplied-pmid 24553523?>
                  <pub-id pub-id-type="pmid">24553523</pub-id>
                </element-citation>
              </ref>
              <ref id="CR5">
                <label>5.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lord</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Midwinter</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Chen</surname>
                      <given-names>Y-F</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The systemic immune response to trauma: an overview of pathophysiology and treatment</article-title>
                  <source>Lancet (London, England)</source>
                  <year>2014</year>
                  <volume>384</volume>
                  <fpage>1455</fpage>
                  <lpage>1465</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0140-6736(14)60687-5</pub-id>
                  <?supplied-pmid 25390327?>
                  <pub-id pub-id-type="pmid">25390327</pub-id>
                </element-citation>
              </ref>
              <ref id="CR6">
                <label>6.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <collab>WHO</collab>
                  </person-group>
                  <source>Guidelines for the treatment of malaria</source>
                  <year>2015</year>
                  <edition>3</edition>
                  <publisher-loc>Geneva</publisher-loc>
                  <publisher-name>World Health Organisation</publisher-name>
                </element-citation>
              </ref>
              <ref id="CR7">
                <label>7.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ho</surname>
                      <given-names>WE</given-names>
                    </name>
                    <name>
                      <surname>Peh</surname>
                      <given-names>HY</given-names>
                    </name>
                    <name>
                      <surname>Chan</surname>
                      <given-names>TK</given-names>
                    </name>
                    <name>
                      <surname>Wong</surname>
                      <given-names>WSF</given-names>
                    </name>
                  </person-group>
                  <article-title>Artemisinins: pharmacological actions beyond anti-malarial</article-title>
                  <source>Pharmacol Ther</source>
                  <year>2014</year>
                  <volume>142</volume>
                  <fpage>126</fpage>
                  <lpage>139</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.pharmthera.2013.12.001</pub-id>
                  <?supplied-pmid 24316259?>
                  <pub-id pub-id-type="pmid">24316259</pub-id>
                </element-citation>
              </ref>
              <ref id="CR8">
                <label>8.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Singh</surname>
                      <given-names>NP</given-names>
                    </name>
                    <name>
                      <surname>Lai</surname>
                      <given-names>H</given-names>
                    </name>
                  </person-group>
                  <article-title>Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells</article-title>
                  <source>Life Sci</source>
                  <year>2001</year>
                  <volume>70</volume>
                  <fpage>49</fpage>
                  <lpage>56</lpage>
                  <pub-id pub-id-type="doi">10.1016/s0024-3205(01)01372-8</pub-id>
                  <?supplied-pmid 11764006?>
                  <pub-id pub-id-type="pmid">11764006</pub-id>
                </element-citation>
              </ref>
              <ref id="CR9">
                <label>9.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Efferth</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Romero</surname>
                      <given-names>MR</given-names>
                    </name>
                    <name>
                      <surname>Wolf</surname>
                      <given-names>DG</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The antiviral activities of artemisinin and artesunate</article-title>
                  <source>Clin Infect Dis</source>
                  <year>2008</year>
                  <volume>47</volume>
                  <fpage>804</fpage>
                  <lpage>811</lpage>
                  <pub-id pub-id-type="doi">10.1086/591195</pub-id>
                  <?supplied-pmid 18699744?>
                  <pub-id pub-id-type="pmid">18699744</pub-id>
                </element-citation>
              </ref>
              <ref id="CR10">
                <label>10.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Moore</surname>
                      <given-names>CM</given-names>
                    </name>
                    <name>
                      <surname>Hoey</surname>
                      <given-names>EM</given-names>
                    </name>
                    <name>
                      <surname>Trudgett</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Timson</surname>
                      <given-names>DJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Artemisinins act through at least two targets in a yeast model</article-title>
                  <source>FEMS Yeast Res</source>
                  <year>2011</year>
                  <volume>11</volume>
                  <fpage>233</fpage>
                  <lpage>237</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.1567-1364.2010.00706.x</pub-id>
                  <?supplied-pmid 21320288?>
                  <pub-id pub-id-type="pmid">21320288</pub-id>
                </element-citation>
              </ref>
              <ref id="CR11">
                <label>11.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ho</surname>
                      <given-names>WE</given-names>
                    </name>
                    <name>
                      <surname>Cheng</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Peh</surname>
                      <given-names>HY</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Anti-malarial drug artesunate ameliorates oxidative lung damage in experimental allergic asthma</article-title>
                  <source>Free Radic Biol Med</source>
                  <year>2012</year>
                  <volume>53</volume>
                  <fpage>498</fpage>
                  <lpage>507</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2012.05.021</pub-id>
                  <?supplied-pmid 22634146?>
                  <pub-id pub-id-type="pmid">22634146</pub-id>
                </element-citation>
              </ref>
              <ref id="CR12">
                <label>12.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Zhao</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Xue</surname>
                      <given-names>D-B</given-names>
                    </name>
                    <name>
                      <surname>Zheng</surname>
                      <given-names>B</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Induction of apoptosis by artemisinin relieving the severity of inflammation in caerulein-induced acute pancreatitis</article-title>
                  <source>World J Gastroenterol</source>
                  <year>2007</year>
                  <volume>13</volume>
                  <fpage>5612</fpage>
                  <lpage>5617</lpage>
                  <pub-id pub-id-type="doi">10.3748/wjg.v13.i42.5612</pub-id>
                  <?supplied-pmid 17948936?>
                  <pub-id pub-id-type="pmid">17948936</pub-id>
                </element-citation>
              </ref>
              <ref id="CR13">
                <label>13.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Li</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>Y</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Inhibitory effect of the antimalarial agent artesunate on collagen-induced arthritis in rats through nuclear factor kappa B and mitogen-activated protein kinase signaling pathway</article-title>
                  <source>Transl Res</source>
                  <year>2013</year>
                  <volume>161</volume>
                  <fpage>89</fpage>
                  <lpage>98</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.trsl.2012.06.001</pub-id>
                  <?supplied-pmid 22749778?>
                  <pub-id pub-id-type="pmid">22749778</pub-id>
                </element-citation>
              </ref>
              <ref id="CR14">
                <label>14.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Li</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Yu</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Pan</surname>
                      <given-names>X</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Artesunate reduces serum lipopolysaccharide in cecal ligation/puncture mice via enhanced LPS internalization by macrophages through increased mRNA expression of scavenger receptors</article-title>
                  <source>Int J Mol Sci</source>
                  <year>2014</year>
                  <volume>15</volume>
                  <fpage>1143</fpage>
                  <lpage>1161</lpage>
                  <pub-id pub-id-type="doi">10.3390/ijms15011143</pub-id>
                  <?supplied-pmid 24441569?>
                  <pub-id pub-id-type="pmid">24441569</pub-id>
                </element-citation>
              </ref>
              <ref id="CR15">
                <label>15.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sordi</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Nandra</surname>
                      <given-names>KK</given-names>
                    </name>
                    <name>
                      <surname>Chiazza</surname>
                      <given-names>F</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Artesunate protects against the organ injury and dysfunction induced by severe hemorrhage and resuscitation</article-title>
                  <source>Ann Surg</source>
                  <year>2017</year>
                  <volume>265</volume>
                  <fpage>408</fpage>
                  <lpage>417</lpage>
                  <pub-id pub-id-type="doi">10.1097/SLA.0000000000001664</pub-id>
                  <?supplied-pmid 28059970?>
                  <pub-id pub-id-type="pmid">28059970</pub-id>
                </element-citation>
              </ref>
              <ref id="CR16">
                <label>16.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Khan</surname>
                      <given-names>AI</given-names>
                    </name>
                    <name>
                      <surname>Kapoor</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Chen</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The antimalarial drug artesunate attenuates cardiac injury in a rodent model of myocardial infarction</article-title>
                  <source>Shock</source>
                  <year>2018</year>
                  <volume>49</volume>
                  <fpage>675</fpage>
                  <lpage>681</lpage>
                  <pub-id pub-id-type="doi">10.1097/SHK.0000000000000963</pub-id>
                  <?supplied-pmid 29757923?>
                  <pub-id pub-id-type="pmid">29757923</pub-id>
                </element-citation>
              </ref>
              <ref id="CR17">
                <label>17.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cabrera</surname>
                      <given-names>CP</given-names>
                    </name>
                    <name>
                      <surname>Manson</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Shepherd</surname>
                      <given-names>JM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Signatures of inflammation and impending multiple organ dysfunction in the hyperacute phase of trauma: a prospective cohort study</article-title>
                  <source>PLoS Med</source>
                  <year>2017</year>
                  <volume>14</volume>
                  <fpage>e1002352</fpage>
                  <pub-id pub-id-type="doi">10.1371/journal.pmed.1002352</pub-id>
                  <?supplied-pmid 28715416?>
                  <pub-id pub-id-type="pmid">28715416</pub-id>
                </element-citation>
              </ref>
              <ref id="CR18">
                <label>18.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rosenthal</surname>
                      <given-names>PJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Artesunate for the treatment of severe falciparum malaria</article-title>
                  <source>N Engl J Med</source>
                  <year>2008</year>
                  <volume>358</volume>
                  <fpage>1829</fpage>
                  <lpage>1836</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJMct0709050</pub-id>
                  <?supplied-pmid 18434652?>
                  <pub-id pub-id-type="pmid">18434652</pub-id>
                </element-citation>
              </ref>
              <ref id="CR19">
                <label>19.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Li</surname>
                      <given-names>Q</given-names>
                    </name>
                    <name>
                      <surname>Melendez</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Cantilena</surname>
                      <given-names>LR</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Pharmacokinetic profiles of artesunate after single intravenous doses at 0.5, 1, 2, 4, and 8 mg/kg in healthy volunteers: a phase i study</article-title>
                  <source>Am J Trop Med Hyg</source>
                  <year>2009</year>
                  <volume>81</volume>
                  <fpage>615</fpage>
                  <lpage>621</lpage>
                  <pub-id pub-id-type="doi">10.4269/ajtmh.2009.09-0150</pub-id>
                  <?supplied-pmid 19815876?>
                  <pub-id pub-id-type="pmid">19815876</pub-id>
                </element-citation>
              </ref>
              <ref id="CR20">
                <label>20.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Miller</surname>
                      <given-names>RS</given-names>
                    </name>
                    <name>
                      <surname>Li</surname>
                      <given-names>Q</given-names>
                    </name>
                    <name>
                      <surname>Cantilena</surname>
                      <given-names>LR</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Pharmacokinetic profiles of artesunate following multiple intravenous doses of 2, 4, and 8 mg/kg in healthy volunteers: phase 1b study</article-title>
                  <source>Malar J</source>
                  <year>2012</year>
                  <volume>11</volume>
                  <fpage>255</fpage>
                  <pub-id pub-id-type="doi">10.1186/1475-2875-11-255</pub-id>
                  <?supplied-pmid 22853818?>
                  <pub-id pub-id-type="pmid">22853818</pub-id>
                </element-citation>
              </ref>
              <ref id="CR21">
                <label>21.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Deeken</surname>
                      <given-names>JF</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Hartley</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies</article-title>
                  <source>Cancer Chemother Pharmacol</source>
                  <year>2018</year>
                  <volume>81</volume>
                  <fpage>587</fpage>
                  <lpage>596</lpage>
                  <pub-id pub-id-type="doi">10.1007/s00280-018-3533-8</pub-id>
                  <?supplied-pmid 29392450?>
                  <pub-id pub-id-type="pmid">29392450</pub-id>
                </element-citation>
              </ref>
              <ref id="CR22">
                <label>22.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dondorp</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Nosten</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Stepniewska</surname>
                      <given-names>K</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial</article-title>
                  <source>Lancet</source>
                  <year>2005</year>
                  <volume>366</volume>
                  <fpage>717</fpage>
                  <lpage>725</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0140-6736(05)67176-0</pub-id>
                  <?supplied-pmid 16125588?>
                  <pub-id pub-id-type="pmid">16125588</pub-id>
                </element-citation>
              </ref>
              <ref id="CR23">
                <label>23.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dondorp</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>Fanello</surname>
                      <given-names>CI</given-names>
                    </name>
                    <name>
                      <surname>Hendriksen</surname>
                      <given-names>IC</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial</article-title>
                  <source>Lancet</source>
                  <year>2010</year>
                  <volume>376</volume>
                  <fpage>1647</fpage>
                  <lpage>1657</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0140-6736(10)61924-1</pub-id>
                  <?supplied-pmid 21062666?>
                  <pub-id pub-id-type="pmid">21062666</pub-id>
                </element-citation>
              </ref>
              <ref id="CR24">
                <label>24.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Saito</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Mansoor</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Kennon</surname>
                      <given-names>K</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Efficacy and tolerability of artemisinin-based and quinine-based treatments for uncomplicated falciparum malaria in pregnancy: a systematic review and individual patient data meta-analysis</article-title>
                  <source>Lancet Infect Dis</source>
                  <year>2020</year>
                  <volume>20</volume>
                  <fpage>943</fpage>
                  <lpage>952</lpage>
                  <pub-id pub-id-type="doi">10.1016/S1473-3099(20)30064-5</pub-id>
                  <?supplied-pmid 32530424?>
                  <pub-id pub-id-type="pmid">32530424</pub-id>
                </element-citation>
              </ref>
              <ref id="CR25">
                <label>25.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ribeiro</surname>
                      <given-names>IR</given-names>
                    </name>
                    <name>
                      <surname>Olliaro</surname>
                      <given-names>P</given-names>
                    </name>
                  </person-group>
                  <article-title>Safety of artemisinin and its derivatives. A review of published and unpublished clinical trials</article-title>
                  <source>Med Trop (Mars)</source>
                  <year>1998</year>
                  <volume>58</volume>
                  <fpage>50</fpage>
                  <lpage>53</lpage>
                  <?supplied-pmid 10212898?>
                  <pub-id pub-id-type="pmid">10212898</pub-id>
                </element-citation>
              </ref>
              <ref id="CR26">
                <label>26.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>McIntosh</surname>
                      <given-names>HM</given-names>
                    </name>
                    <name>
                      <surname>Olliaro</surname>
                      <given-names>P</given-names>
                    </name>
                  </person-group>
                  <article-title>Artemisinin derivatives for treating severe malaria</article-title>
                  <source>Cochrane Database Syst Rev</source>
                  <year>2000</year>
                  <volume>1998</volume>
                  <fpage>CD000527</fpage>
                  <pub-id pub-id-type="doi">10.1002/14651858.CD000527</pub-id>
                  <?supplied-pmid 10796551?>
                  <pub-id pub-id-type="pmid">10796551</pub-id>
                </element-citation>
              </ref>
              <ref id="CR27">
                <label>27.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sinclair</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Donegan</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Isba</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Lalloo</surname>
                      <given-names>DG</given-names>
                    </name>
                  </person-group>
                  <article-title>Artesunate versus quinine for treating severe malaria</article-title>
                  <source>Cochrane Database Syst Rev</source>
                  <year>2012</year>
                  <volume>2012</volume>
                  <fpage>CD005967</fpage>
                  <pub-id pub-id-type="doi">10.1002/14651858.CD005967.pub4</pub-id>
                  <?supplied-pmid 22696354?>
                  <pub-id pub-id-type="pmid">22696354</pub-id>
                </element-citation>
              </ref>
              <ref id="CR28">
                <label>28.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Schulz</surname>
                      <given-names>KF</given-names>
                    </name>
                    <name>
                      <surname>Altman</surname>
                      <given-names>DG</given-names>
                    </name>
                    <name>
                      <surname>Moher</surname>
                      <given-names>D</given-names>
                    </name>
                  </person-group>
                  <article-title>CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials</article-title>
                  <source>BMJ</source>
                  <year>2010</year>
                  <volume>340</volume>
                  <fpage>c332</fpage>
                  <lpage>c332</lpage>
                  <pub-id pub-id-type="doi">10.1136/bmj.c332</pub-id>
                  <?supplied-pmid 20332509?>
                  <pub-id pub-id-type="pmid">20332509</pub-id>
                </element-citation>
              </ref>
              <ref id="CR29">
                <label>29.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Minei</surname>
                      <given-names>JP</given-names>
                    </name>
                    <name>
                      <surname>Cuschieri</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Sperry</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The changing pattern and implications of multiple organ failure after blunt injury with hemorrhagic shock*</article-title>
                  <source>Crit Care Med</source>
                  <year>2012</year>
                  <volume>40</volume>
                  <fpage>1129</fpage>
                  <lpage>1135</lpage>
                  <pub-id pub-id-type="doi">10.1097/CCM.0b013e3182376e9f</pub-id>
                  <?supplied-pmid 22020243?>
                  <pub-id pub-id-type="pmid">22020243</pub-id>
                </element-citation>
              </ref>
              <ref id="CR30">
                <label>30.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <collab>Department of Constitutional Affairs</collab>
                  </person-group>
                  <source>Mental capacity act 2005 code of practice</source>
                  <year>2007</year>
                  <publisher-loc>London</publisher-loc>
                  <publisher-name>London Stationary Office</publisher-name>
                </element-citation>
              </ref>
              <ref id="CR31">
                <label>31.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <collab>World Medical Association</collab>
                  </person-group>
                  <article-title>World Medical Association Declaration of Helsinki</article-title>
                  <source>JAMA</source>
                  <year>2013</year>
                  <volume>310</volume>
                  <fpage>2191</fpage>
                  <pub-id pub-id-type="doi">10.1001/jama.2013.281053</pub-id>
                  <pub-id pub-id-type="pmid">24141714</pub-id>
                </element-citation>
              </ref>
              <ref id="CR32">
                <label>32.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Baker</surname>
                      <given-names>SP</given-names>
                    </name>
                    <name>
                      <surname>O’Neill</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Haddon</surname>
                      <given-names>W</given-names>
                      <suffix>Jr</suffix>
                    </name>
                    <name>
                      <surname>Long</surname>
                      <given-names>WB</given-names>
                    </name>
                  </person-group>
                  <article-title>The injury severity score: a method for describing patients with multiple injuries and evaluating emergency care</article-title>
                  <source>J Trauma</source>
                  <year>1974</year>
                  <volume>14</volume>
                  <fpage>187</fpage>
                  <lpage>269</lpage>
                  <pub-id pub-id-type="doi">10.1097/00005373-197403000-00001</pub-id>
                  <?supplied-pmid 4814394?>
                  <pub-id pub-id-type="pmid">4814394</pub-id>
                </element-citation>
              </ref>
              <ref id="CR33">
                <label>33.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Vincent</surname>
                      <given-names>J-L</given-names>
                    </name>
                    <name>
                      <surname>Moreno</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Takala</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure</article-title>
                  <source>Intensive Care Med</source>
                  <year>1996</year>
                  <volume>22</volume>
                  <fpage>707</fpage>
                  <lpage>710</lpage>
                  <pub-id pub-id-type="doi">10.1007/BF01709751</pub-id>
                  <?supplied-pmid 8844239?>
                  <pub-id pub-id-type="pmid">8844239</pub-id>
                </element-citation>
              </ref>
              <ref id="CR34">
                <label>34.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Liu</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Namas</surname>
                      <given-names>RA</given-names>
                    </name>
                    <name>
                      <surname>Vodovotz</surname>
                      <given-names>Y</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Unsupervised clustering analysis based on MODS severity identifies four distinct organ dysfunction patterns in severely injured blunt trauma patients</article-title>
                  <source>Front Med</source>
                  <year>2020</year>
                  <volume>7</volume>
                  <fpage>46</fpage>
                  <pub-id pub-id-type="doi">10.3389/fmed.2020.00046</pub-id>
                </element-citation>
              </ref>
              <ref id="CR35">
                <label>35.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nadel</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Goldstein</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Williams</surname>
                      <given-names>MD</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial</article-title>
                  <source>Lancet</source>
                  <year>2007</year>
                  <volume>369</volume>
                  <fpage>836</fpage>
                  <lpage>843</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0140-6736(07)60411-5</pub-id>
                  <?supplied-pmid 17350452?>
                  <pub-id pub-id-type="pmid">17350452</pub-id>
                </element-citation>
              </ref>
              <ref id="CR36">
                <label>36.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yehya</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Harhay</surname>
                      <given-names>MO</given-names>
                    </name>
                    <name>
                      <surname>Curley</surname>
                      <given-names>MAQ</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Reappraisal of ventilator-free days in critical care research</article-title>
                  <source>Am J Respir Crit Care Med</source>
                  <year>2019</year>
                  <volume>200</volume>
                  <fpage>828</fpage>
                  <lpage>836</lpage>
                  <pub-id pub-id-type="doi">10.1164/rccm.201810-2050CP</pub-id>
                  <?supplied-pmid 31034248?>
                  <pub-id pub-id-type="pmid">31034248</pub-id>
                </element-citation>
              </ref>
              <ref id="CR37">
                <label>37.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Definition Task Force</surname>
                      <given-names>ARDS</given-names>
                    </name>
                    <name>
                      <surname>Ranieri</surname>
                      <given-names>VM</given-names>
                    </name>
                    <name>
                      <surname>Rubenfeld</surname>
                      <given-names>GD</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Acute respiratory distress syndrome: the Berlin definition</article-title>
                  <source>JAMA</source>
                  <year>2012</year>
                  <volume>307</volume>
                  <fpage>2526</fpage>
                  <lpage>2533</lpage>
                  <pub-id pub-id-type="doi">10.1001/jama.2012.5669</pub-id>
                  <pub-id pub-id-type="pmid">22797452</pub-id>
                </element-citation>
              </ref>
              <ref id="CR38">
                <label>38.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bellomo</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Ronco</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Kellum</surname>
                      <given-names>JA</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group</article-title>
                  <source>Crit Care</source>
                  <year>2004</year>
                  <volume>8</volume>
                  <fpage>R204</fpage>
                  <lpage>R212</lpage>
                  <pub-id pub-id-type="doi">10.1186/cc2872</pub-id>
                  <?supplied-pmid 15312219?>
                  <pub-id pub-id-type="pmid">15312219</pub-id>
                </element-citation>
              </ref>
              <ref id="CR39">
                <label>39.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cole</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Davenport</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Willett</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Brohi</surname>
                      <given-names>K</given-names>
                    </name>
                  </person-group>
                  <article-title>The burden of infection in severely injured trauma patients and the relationship with admission shock severity</article-title>
                  <source>J Trauma Acute Care Surg</source>
                  <year>2014</year>
                  <volume>76</volume>
                  <fpage>730</fpage>
                  <lpage>735</lpage>
                  <pub-id pub-id-type="doi">10.1097/TA.0b013e31829fdbd7</pub-id>
                  <?supplied-pmid 24487318?>
                  <pub-id pub-id-type="pmid">24487318</pub-id>
                </element-citation>
              </ref>
              <ref id="CR40">
                <label>40.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Newcombe</surname>
                      <given-names>RG</given-names>
                    </name>
                  </person-group>
                  <article-title>Interval estimation for the difference between independent proportions: comparison of eleven methods</article-title>
                  <source>Stat Med</source>
                  <year>1998</year>
                  <volume>17</volume>
                  <fpage>873</fpage>
                  <lpage>890</lpage>
                  <pub-id pub-id-type="doi">10.1002/(sici)1097-0258(19980430)17:8&lt;873::aid-sim779&gt;3.0.co;2-i</pub-id>
                  <?supplied-pmid 9595617?>
                  <pub-id pub-id-type="pmid">9595617</pub-id>
                </element-citation>
              </ref>
              <ref id="CR41">
                <label>41.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hanpithakpong</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Kamanikom</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Dondorp</surname>
                      <given-names>AM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>A liquid chromatographic-tandem mass spectrometric method for determination of artesunate and its metabolite dihydroartemisinin in human plasma</article-title>
                  <source>J Chromatogr B Analyt Technol Biomed Life Sci</source>
                  <year>2008</year>
                  <volume>876</volume>
                  <fpage>61</fpage>
                  <lpage>68</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.jchromb.2008.10.018</pub-id>
                  <?supplied-pmid 18990614?>
                  <pub-id pub-id-type="pmid">18990614</pub-id>
                </element-citation>
              </ref>
              <ref id="CR42">
                <label>42.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Frith</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Goslings</surname>
                      <given-names>JC</given-names>
                    </name>
                    <name>
                      <surname>Gaarder</surname>
                      <given-names>C</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Definition and drivers of acute traumatic coagulopathy: clinical and experimental investigations</article-title>
                  <source>J Thromb Haemost</source>
                  <year>2010</year>
                  <volume>8</volume>
                  <fpage>1919</fpage>
                  <lpage>1925</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.1538-7836.2010.03945.x</pub-id>
                  <?supplied-pmid 20553376?>
                  <pub-id pub-id-type="pmid">20553376</pub-id>
                </element-citation>
              </ref>
              <ref id="CR43">
                <label>43.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hamada</surname>
                      <given-names>SR</given-names>
                    </name>
                    <name>
                      <surname>Espina</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Guedj</surname>
                      <given-names>T</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>High level of venous thromboembolism in critically ill trauma patients despite early and well-driven thromboprophylaxis protocol</article-title>
                  <source>Ann Intensive Care</source>
                  <year>2017</year>
                  <volume>7</volume>
                  <fpage>97</fpage>
                  <pub-id pub-id-type="doi">10.1186/s13613-017-0315-0</pub-id>
                  <?supplied-pmid 28900890?>
                  <pub-id pub-id-type="pmid">28900890</pub-id>
                </element-citation>
              </ref>
              <ref id="CR44">
                <label>44.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Moore</surname>
                      <given-names>EE</given-names>
                    </name>
                    <name>
                      <surname>Moore</surname>
                      <given-names>HB</given-names>
                    </name>
                    <name>
                      <surname>Kornblith</surname>
                      <given-names>LZ</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Trauma-induced coagulopathy</article-title>
                  <source>Nat Rev Dis Prim</source>
                  <year>2021</year>
                  <volume>7</volume>
                  <fpage>30</fpage>
                  <pub-id pub-id-type="doi">10.1038/s41572-021-00264-3</pub-id>
                  <?supplied-pmid 33927200?>
                  <pub-id pub-id-type="pmid">33927200</pub-id>
                </element-citation>
              </ref>
              <ref id="CR45">
                <label>45.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Geerts</surname>
                      <given-names>WH</given-names>
                    </name>
                    <name>
                      <surname>Code</surname>
                      <given-names>KI</given-names>
                    </name>
                    <name>
                      <surname>Jay</surname>
                      <given-names>RM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>A prospective study of venous thromboembolism after major trauma</article-title>
                  <source>N Engl J Med</source>
                  <year>1994</year>
                  <volume>331</volume>
                  <fpage>1601</fpage>
                  <lpage>1606</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJM199412153312401</pub-id>
                  <?supplied-pmid 7969340?>
                  <pub-id pub-id-type="pmid">7969340</pub-id>
                </element-citation>
              </ref>
              <ref id="CR46">
                <label>46.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Jacobs</surname>
                      <given-names>BN</given-names>
                    </name>
                    <name>
                      <surname>Cain-Nielsen</surname>
                      <given-names>AH</given-names>
                    </name>
                    <name>
                      <surname>Jakubus</surname>
                      <given-names>JL</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Unfractionated heparin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in trauma</article-title>
                  <source>J Trauma Acute Care Surg</source>
                  <year>2017</year>
                  <volume>83</volume>
                  <fpage>151</fpage>
                  <lpage>158</lpage>
                  <pub-id pub-id-type="doi">10.1097/TA.0000000000001494</pub-id>
                  <?supplied-pmid 28426561?>
                  <pub-id pub-id-type="pmid">28426561</pub-id>
                </element-citation>
              </ref>
              <ref id="CR47">
                <label>47.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Xiao</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Mindrinos</surname>
                      <given-names>MN</given-names>
                    </name>
                    <name>
                      <surname>Seok</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>A genomic storm in critically injured humans</article-title>
                  <source>J Exp Med</source>
                  <year>2011</year>
                  <volume>208</volume>
                  <fpage>2581</fpage>
                  <lpage>2590</lpage>
                  <pub-id pub-id-type="doi">10.1084/jem.20111354</pub-id>
                  <?supplied-pmid 22110166?>
                  <pub-id pub-id-type="pmid">22110166</pub-id>
                </element-citation>
              </ref>
              <ref id="CR48">
                <label>48.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pfeifer</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Teuben</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Andruszkow</surname>
                      <given-names>H</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Mortality patterns in patients with multiple trauma: a systematic review of autopsy Studies</article-title>
                  <source>PLoS One</source>
                  <year>2016</year>
                  <volume>11</volume>
                  <fpage>1</fpage>
                  <lpage>9</lpage>
                  <pub-id pub-id-type="doi">10.1371/journal.pone.0148844</pub-id>
                </element-citation>
              </ref>
              <ref id="CR49">
                <label>49.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Eriksson</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Nelson</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Holst</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Temporal patterns of organ dysfunction after severe trauma</article-title>
                  <source>Crit Care</source>
                  <year>2021</year>
                  <volume>25</volume>
                  <fpage>165</fpage>
                  <pub-id pub-id-type="doi">10.1186/s13054-021-03586-6</pub-id>
                  <?supplied-pmid 33952314?>
                  <pub-id pub-id-type="pmid">33952314</pub-id>
                </element-citation>
              </ref>
              <ref id="CR50">
                <label>50.</label>
                <mixed-citation publication-type="other">Centre for Trauma Sciences Activation of Inflammation and Coagulation in Trauma (ACIT). <ext-link ext-link-type="uri" xlink:href="https://www.c4ts.qmul.ac.uk/research-programmes/acit">https://www.c4ts.qmul.ac.uk/research-programmes/acit</ext-link>. Accessed 1 Oct 2021</mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
